Author

Craig Herrman

Observed names: C. E. Herrman, Craig E Herrman, Herrman, Craig E

OpenAlex ID: A5000507198

Adjunctive perampanel for refractory partial-onset seizures

2012 · Jacqueline A. French, Gregory L. Krauss, et al. · Neurology · 481

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

2018 · Raju Kapoor, Pei-Ran Ho, et al. · The Lancet Neurology · 342

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

2016 · Robert J. Fox, Andrew Chan, et al. · Neurology Clinical Practice · 105

Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study

2021 · Amit Bar-Or, Heinz Wiendl, et al. · Multiple Sclerosis Journal · 69

Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study

2010 · G. Anderson, D. Meyer, et al. · Journal of Neurology · 26

Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study

2011 · Sibyl Wray, Robert Armstrong, et al. · Expert Opinion on Drug Delivery · 17

Efficacy and Safety of a Modified Ublituximab Regimen (ENHANCE) (P11-1.009)

2025 · John Foley, Tamara Miller, et al. · Neurology · 1

Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)

2026 · Barry Singer, Craig Herrman, et al. · Neurology

An Interim Analysis of Efficacy and Safety Data in Black and Hispanic Patients With Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial (S31.006)

2023 · Evanthia Bernitsas, Anthony Reder, et al. · Neurology

Works count: 11

Citation count: 1,041

H-index: 6

I10-index: 6